Header Logo

Connection

JAMES WELSH to Humans

Back to Details
This is a "connection" page, showing publications JAMES WELSH has written about Humans.
JAMES WELSH
Connection Strength
1.236
Humans
  1. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology. 2024 Oct 01; 22(1):597.
    View in: PubMed
    Score: 0.019
  2. Is Single-Site Radiation Therapy Enough to Augment the Immune System and Enhance Immunotherapy for Metastatic Disease? Semin Radiat Oncol. 2024 Jul; 34(3):272-275.
    View in: PubMed
    Score: 0.019
  3. Durable control of metastases in an HLA-A2+ patient with refractory melanoma after low-dose radiotherapy in combination with MAGE-A4 T cell therapy: a case report. Melanoma Res. 2023 08 01; 33(4):332-337.
    View in: PubMed
    Score: 0.017
  4. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
    View in: PubMed
    Score: 0.017
  5. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol. 2023 06; 183:109618.
    View in: PubMed
    Score: 0.017
  6. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
    View in: PubMed
    Score: 0.016
  7. Local Therapy for Oligoprogressive Disease: A Systematic Review of Prospective Trials. Int J Radiat Oncol Biol Phys. 2022 11 15; 114(4):676-683.
    View in: PubMed
    Score: 0.016
  8. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol. 2021; 12:812210.
    View in: PubMed
    Score: 0.016
  9. Comments on "Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India". Radiother Oncol. 2022 02; 167:323-324.
    View in: PubMed
    Score: 0.016
  10. In Regard to Shuryak et al. Int J Radiat Oncol Biol Phys. 2021 10 01; 111(2):574-576.
    View in: PubMed
    Score: 0.015
  11. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
    View in: PubMed
    Score: 0.015
  12. Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. Semin Radiat Oncol. 2021 07; 31(3):217-226.
    View in: PubMed
    Score: 0.015
  13. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021 05; 9(5):467-475.
    View in: PubMed
    Score: 0.014
  14. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol. 2020; 11:573326.
    View in: PubMed
    Score: 0.014
  15. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.014
  16. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.014
  17. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
    View in: PubMed
    Score: 0.014
  18. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. J Thorac Oncol. 2020 12; 15(12):1919-1927.
    View in: PubMed
    Score: 0.014
  19. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
    View in: PubMed
    Score: 0.014
  20. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy. Radiother Oncol. 2020 09; 150:114-120.
    View in: PubMed
    Score: 0.014
  21. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.014
  22. Using Real-World Historical Controls to Evaluate Radiation Dose Escalation in Esophageal Cancer-Reply. JAMA Oncol. 2020 04 01; 6(4):583-584.
    View in: PubMed
    Score: 0.014
  23. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 09 01; 108(1):196-203.
    View in: PubMed
    Score: 0.014
  24. Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials. J Immunother Cancer. 2020 Jan; 8(1).
    View in: PubMed
    Score: 0.014
  25. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. JAMA Oncol. 2019 11 01; 5(11):1597-1604.
    View in: PubMed
    Score: 0.013
  26. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
    View in: PubMed
    Score: 0.013
  27. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2020 02; 15(2):266-273.
    View in: PubMed
    Score: 0.013
  28. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
    View in: PubMed
    Score: 0.013
  29. Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. Pract Radiat Oncol. 2020 Sep - Oct; 10(5):324-329.
    View in: PubMed
    Score: 0.013
  30. Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. J Immunother. 2019 Feb/Mar; 42(2):55-64.
    View in: PubMed
    Score: 0.013
  31. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Front Immunol. 2018; 9:2170.
    View in: PubMed
    Score: 0.012
  32. Glycosylation and Antitumor Immunity. Int Rev Cell Mol Biol. 2019; 343:111-127.
    View in: PubMed
    Score: 0.012
  33. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 11 15; 24(22):5735-5743.
    View in: PubMed
    Score: 0.012
  34. Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1141-1148.
    View in: PubMed
    Score: 0.012
  35. Optimizing Radiotherapy with Immunotherapeutic Approaches. Adv Exp Med Biol. 2017; 995:53-71.
    View in: PubMed
    Score: 0.011
  36. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.011
  37. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. J Thorac Oncol. 2017 02; 12(2):375-382.
    View in: PubMed
    Score: 0.011
  38. Galectin-1 and immune suppression during radiotherapy. Clin Cancer Res. 2014 Dec 15; 20(24):6230-2.
    View in: PubMed
    Score: 0.009
  39. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
    View in: PubMed
    Score: 0.009
  40. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
    View in: PubMed
    Score: 0.009
  41. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014 Aug; 22(8):1494-1503.
    View in: PubMed
    Score: 0.009
  42. Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study. Strahlenther Onkol. 2014 Oct; 190(11):979-86.
    View in: PubMed
    Score: 0.009
  43. Clinical cancer genetics. Part 2: Breast. Am J Clin Oncol. 2014 Feb; 37(1):86-9.
    View in: PubMed
    Score: 0.009
  44. Factors associated with local-regional failure after definitive chemoradiation for locally advanced esophageal cancer. Ann Surg Oncol. 2014 Jan; 21(1):306-14.
    View in: PubMed
    Score: 0.009
  45. Cardiac ?8F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiother Oncol. 2013 Oct; 109(1):82-8.
    View in: PubMed
    Score: 0.009
  46. Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol. 2013 Sep 01; 31(25):3165-6.
    View in: PubMed
    Score: 0.009
  47. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol. 2013 Mar; 106(3):327-32.
    View in: PubMed
    Score: 0.008
  48. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013 May 15; 119(10):1768-75.
    View in: PubMed
    Score: 0.008
  49. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.008
  50. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.008
  51. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 2012 Aug; 7(8):1211-7.
    View in: PubMed
    Score: 0.008
  52. Correlation of three different approaches of small bowel delineation and acute lower gastrointestinal toxicity in adjuvant pelvic intensity-modulated radiation therapy for endometrial cancer. Technol Cancer Res Treat. 2012 Aug; 11(4):353-9.
    View in: PubMed
    Score: 0.008
  53. Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e231-9.
    View in: PubMed
    Score: 0.008
  54. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 01; 82(3):e391-8.
    View in: PubMed
    Score: 0.008
  55. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012 May 15; 118(10):2632-40.
    View in: PubMed
    Score: 0.008
  56. Clinical cancer genetics: Part I: Gastrointestinal. Am J Clin Oncol. 2011 Jun; 34(3):332-6.
    View in: PubMed
    Score: 0.008
  57. Update: modern approaches to the treatment of localized esophageal cancer. Curr Oncol Rep. 2011 Jun; 13(3):157-67.
    View in: PubMed
    Score: 0.008
  58. Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1336-42.
    View in: PubMed
    Score: 0.007
  59. Dosimetric and clinical review of helical tomotherapy. Expert Rev Anticancer Ther. 2011 Feb; 11(2):309-20.
    View in: PubMed
    Score: 0.007
  60. Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys. 2012 Jan 01; 82(1):468-74.
    View in: PubMed
    Score: 0.007
  61. A planning study for palliative spine treatment using StatRT and megavoltage CT simulation. J Appl Clin Med Phys. 2010 Oct 30; 12(1):3348.
    View in: PubMed
    Score: 0.007
  62. Surface applicator calibration and commissioning of an electronic brachytherapy system for nonmelanoma skin cancer treatment. Med Phys. 2010 Oct; 37(10):5509-17.
    View in: PubMed
    Score: 0.007
  63. Treatment planning for pulsed reduced dose-rate radiotherapy in helical tomotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 01; 79(3):934-42.
    View in: PubMed
    Score: 0.007
  64. Obesity increases the risk of chest wall pain from thoracic stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):91-6.
    View in: PubMed
    Score: 0.007
  65. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009 Dec 22; 4:69.
    View in: PubMed
    Score: 0.007
  66. Rad51 protein expression and survival in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 2009 Jul 15; 74(4):1251-5.
    View in: PubMed
    Score: 0.007
  67. Clinical, technical, and basic science progress in helical tomotherapy--the pace continues to accelerate. Technol Cancer Res Treat. 2009 Feb; 8(1):1-2.
    View in: PubMed
    Score: 0.006
  68. Multimodality image guided total marrow irradiation and verification of the dose delivered to the lung, PTV, and thoracic bone in a patient: a case study. Technol Cancer Res Treat. 2009 Feb; 8(1):23-8.
    View in: PubMed
    Score: 0.006
  69. Hypofractionated breast and chest wall irradiation using simultaneous in-field boost IMRT delivered via helical tomotherapy. Technol Cancer Res Treat. 2008 Dec; 7(6):433-9.
    View in: PubMed
    Score: 0.006
  70. Basics of particle therapy: introduction to hadrons. Am J Clin Oncol. 2008 Oct; 31(5):493-5.
    View in: PubMed
    Score: 0.006
  71. Image-guided hypofractionated simultaneous in-field boost breast IMRT: in regard to Freedman et al. (Int J Radiat Oncol Biol Phys 2007;68:347-353). Int J Radiat Oncol Biol Phys. 2007 Nov 01; 69(3):962; author reply 963.
    View in: PubMed
    Score: 0.006
  72. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys. 2007 May 01; 68(1):159-65.
    View in: PubMed
    Score: 0.006
  73. Clinical implementation of adaptive helical tomotherapy: a unique approach to image-guided intensity modulated radiotherapy. Technol Cancer Res Treat. 2006 Oct; 5(5):465-79.
    View in: PubMed
    Score: 0.005
  74. Selective Internal Radiation Therapy (SIRT) for liver metastases secondary to colorectal adenocarcinoma. Int J Radiat Oncol Biol Phys. 2006; 66(2 Suppl):S62-73.
    View in: PubMed
    Score: 0.005
  75. Helical tomotherapy as a means of delivering scalp-sparing whole brain radiation therapy. Technol Cancer Res Treat. 2005 Dec; 4(6):661-2; author reply 662.
    View in: PubMed
    Score: 0.005
  76. Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. J Immunother Cancer. 2024 Oct 09; 12(10).
    View in: PubMed
    Score: 0.005
  77. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
    View in: PubMed
    Score: 0.005
  78. Hybridizing mechanistic modeling and deep learning for personalized survival prediction after immune checkpoint inhibitor immunotherapy. NPJ Syst Biol Appl. 2024 Aug 14; 10(1):88.
    View in: PubMed
    Score: 0.005
  79. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy. Technol Cancer Res Treat. 2004 Aug; 3(4):359-64.
    View in: PubMed
    Score: 0.005
  80. A Systematic Review of Clinical Trials Comparing Radiation Therapy Versus Radical Prostatectomy in Prostate Cancer. Clin Genitourin Cancer. 2024 Oct; 22(5):102157.
    View in: PubMed
    Score: 0.005
  81. Megavoltage computed tomography imaging: a potential tool to guide and improve the delivery of thoracic radiation therapy. Clin Lung Cancer. 2004 Mar; 5(5):303-6.
    View in: PubMed
    Score: 0.005
  82. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
    View in: PubMed
    Score: 0.005
  83. Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy. Am J Clin Oncol. 2024 04 01; 47(4):155-160.
    View in: PubMed
    Score: 0.004
  84. The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC. Cancer Res Commun. 2023 10 11; 3(10):2074-2081.
    View in: PubMed
    Score: 0.004
  85. Dose rate in external beam radiotherapy for prostate cancer: an overlooked confounding variable? Urology. 2003 Aug; 62(2):204-6.
    View in: PubMed
    Score: 0.004
  86. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.004
  87. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial. J Immunother Cancer. 2023 07; 11(7).
    View in: PubMed
    Score: 0.004
  88. Multi-institutional Development and Validation of Contouring Guidelines for Para-aortic Elective Nodal Irradiation in Prostate Cancer Based on Patterns of Involvement on Targeted Molecular Imaging Positron Emission Tomography/Computed Tomography. Int J Radiat Oncol Biol Phys. 2023 11 01; 117(3):630-640.
    View in: PubMed
    Score: 0.004
  89. The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023; 14:1172931.
    View in: PubMed
    Score: 0.004
  90. Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
    View in: PubMed
    Score: 0.004
  91. Lymphocyte sparing normal tissue effects in the clinic (LymphoTEC): A systematic review of dose constraint considerations to mitigate radiation-related lymphopenia in the era of immunotherapy. Radiother Oncol. 2022 12; 177:81-94.
    View in: PubMed
    Score: 0.004
  92. Helical tomotherapy: an innovative technology and approach to radiation therapy. Technol Cancer Res Treat. 2002 Aug; 1(4):311-6.
    View in: PubMed
    Score: 0.004
  93. A Systematic Review of the Cost-Effectiveness of Stereotactic Radiation Therapy for Cancer Oligometastases. Int J Radiat Oncol Biol Phys. 2022 12 01; 114(5):977-988.
    View in: PubMed
    Score: 0.004
  94. Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncol. 2022 04; 23(4):e156.
    View in: PubMed
    Score: 0.004
  95. Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. Acta Oncol. 2022 Apr; 61(4):403-408.
    View in: PubMed
    Score: 0.004
  96. A comparison of proton stopping power measured with proton CT and x-ray CT in fresh postmortem porcine structures. Med Phys. 2021 Dec; 48(12):7998-8009.
    View in: PubMed
    Score: 0.004
  97. Multicenter Study of Antibody Seroprevalence against COVID-19 in Patients Presenting to Iranian Cancer Centers after One Year of the COVID-19 Pandemic. Cancer Invest. 2022 Feb; 40(2):115-123.
    View in: PubMed
    Score: 0.004
  98. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10.
    View in: PubMed
    Score: 0.004
  99. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. Cancer Invest. 2022 Jan; 40(1):26-34.
    View in: PubMed
    Score: 0.004
  100. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Front Immunol. 2021; 12:719285.
    View in: PubMed
    Score: 0.004
  101. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond). 2021 11; 41(11):1086-1099.
    View in: PubMed
    Score: 0.004
  102. Can low-dose radiation therapy reduce the risk of mucormycosis in COVID-19 patients? J Cancer Res Ther. 2021 Oct-Dec; 17(6):1294-1296.
    View in: PubMed
    Score: 0.004
  103. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457.
    View in: PubMed
    Score: 0.004
  104. Low-dose radiation therapy for osteoarthritis and enthesopathies: a review of current data. Int J Radiat Biol. 2021; 97(10):1352-1367.
    View in: PubMed
    Score: 0.004
  105. Low-dose radiation therapy (LDRT) for COVID-19 and its deadlier variants. Arch Toxicol. 2021 10; 95(10):3425-3432.
    View in: PubMed
    Score: 0.004
  106. Financial relationships between industry and principal investigators of US cooperative group randomized cancer clinical trials. Int J Cancer. 2021 11 01; 149(9):1683-1690.
    View in: PubMed
    Score: 0.004
  107. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys. 2021 11 01; 111(3):647-657.
    View in: PubMed
    Score: 0.004
  108. In Regard to Papachristofilou et al. Int J Radiat Oncol Biol Phys. 2021 08 01; 110(5):1550-1551.
    View in: PubMed
    Score: 0.004
  109. Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. Gynecol Oncol. 2021 06; 161(3):645-652.
    View in: PubMed
    Score: 0.004
  110. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
    View in: PubMed
    Score: 0.004
  111. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.004
  112. The Effects of Time to Treatment Initiation for Patients With Non-small-cell Lung Cancer in the United States. Clin Lung Cancer. 2021 01; 22(1):e84-e97.
    View in: PubMed
    Score: 0.004
  113. Radiation-induced lymphopenia during chemoradiation therapy for non-small cell lung cancer is linked with age, lung V5, and XRCC1 rs25487 genotypes in lymphocytes. Radiother Oncol. 2021 01; 154:187-193.
    View in: PubMed
    Score: 0.004
  114. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer. 2000 Jul 01; 89(1):226-7.
    View in: PubMed
    Score: 0.004
  115. Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617. Clin Cancer Res. 2020 09 01; 26(17):4643-4650.
    View in: PubMed
    Score: 0.003
  116. Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. Int J Radiat Oncol Biol Phys. 2020 08 01; 107(5):897-908.
    View in: PubMed
    Score: 0.003
  117. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv. 2020 05; 6(18):eaay6298.
    View in: PubMed
    Score: 0.003
  118. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 07 15; 107(4):766-778.
    View in: PubMed
    Score: 0.003
  119. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open. 2020 04 01; 3(4):e203277.
    View in: PubMed
    Score: 0.003
  120. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020 08; 42(8):1939-1953.
    View in: PubMed
    Score: 0.003
  121. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. Int J Radiat Oncol Biol Phys. 2020 06 01; 107(2):261-269.
    View in: PubMed
    Score: 0.003
  122. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol. 2020 04; 145:178-185.
    View in: PubMed
    Score: 0.003
  123. Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):90-99.
    View in: PubMed
    Score: 0.003
  124. Radiation myositis. Ann Oncol. 1999 Sep; 10(9):1105-8.
    View in: PubMed
    Score: 0.003
  125. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol. 2019 06 01; 5(6):872-878.
    View in: PubMed
    Score: 0.003
  126. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.003
  127. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019 07; 136:136-142.
    View in: PubMed
    Score: 0.003
  128. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019 04; 58(4):244-253.
    View in: PubMed
    Score: 0.003
  129. Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2019 07; 20(4):e480-e488.
    View in: PubMed
    Score: 0.003
  130. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193.
    View in: PubMed
    Score: 0.003
  131. Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis. Radiat Oncol. 2018 Dec 29; 13(1):258.
    View in: PubMed
    Score: 0.003
  132. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018 11 23; 6(1):128.
    View in: PubMed
    Score: 0.003
  133. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019 02; 2(1):79-87.
    View in: PubMed
    Score: 0.003
  134. Altered cancer metabolism in mechanisms of immunotherapy resistance. Pharmacol Ther. 2019 03; 195:162-171.
    View in: PubMed
    Score: 0.003
  135. Letter by Cai et al Regarding Article, "Exposure to Low-Dose Ionizing Radiation From Cardiac Procedures and Malignancy Risk in Adults With Congenital Heart Disease". Circulation. 2018 09 25; 138(13):1377-1378.
    View in: PubMed
    Score: 0.003
  136. Twice-daily Thoracic Radiotherapy for Limited-stage Small-cell Lung Cancer Does Not Increase the Incidence of Acute Severe Esophagitis. Clin Lung Cancer. 2018 11; 19(6):e885-e891.
    View in: PubMed
    Score: 0.003
  137. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
    View in: PubMed
    Score: 0.003
  138. Barriers to Combined-Modality Therapy for Limited-Stage Small Cell Lung Cancer. JAMA Oncol. 2018 08 01; 4(8):e174504.
    View in: PubMed
    Score: 0.003
  139. Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. Immunotherapy. 2018 08; 10(10):851-0.
    View in: PubMed
    Score: 0.003
  140. Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2018 11 01; 102(3):593-600.
    View in: PubMed
    Score: 0.003
  141. Hematologic variables associated with brain failure in patients with small-cell lung cancer. Radiother Oncol. 2018 09; 128(3):505-512.
    View in: PubMed
    Score: 0.003
  142. Lung Cancer: Posttreatment Imaging: Radiation Therapy and Imaging Findings. Radiol Clin North Am. 2018 May; 56(3):471-483.
    View in: PubMed
    Score: 0.003
  143. Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017. Clin Cancer Res. 2018 08 01; 24(15):3500-3509.
    View in: PubMed
    Score: 0.003
  144. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.003
  145. Cost Analysis of PET/CT Versus CT as Surveillance for Stage III Non-Small-Cell Lung Cancer After Definitive Radiation Therapy. Clin Lung Cancer. 2018 07; 19(4):e517-e528.
    View in: PubMed
    Score: 0.003
  146. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018 Mar; 126(3):499-505.
    View in: PubMed
    Score: 0.003
  147. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018 02 01; 10(4):299-316.
    View in: PubMed
    Score: 0.003
  148. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922.
    View in: PubMed
    Score: 0.003
  149. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017 10; 125(1):80-88.
    View in: PubMed
    Score: 0.003
  150. Radiation Oncology Resident Mentorship: Results of a Resident-Coordinated Mentorship?Program. J Am Coll Radiol. 2017 12; 14(12):1607-1610.
    View in: PubMed
    Score: 0.003
  151. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.003
  152. Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival. J Thorac Oncol. 2017 11; 12(11):1696-1703.
    View in: PubMed
    Score: 0.003
  153. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):128-135.
    View in: PubMed
    Score: 0.003
  154. Webinar-Based Contouring Education for?Residents. J Am Coll Radiol. 2017 Aug; 14(8):1074-1079.e3.
    View in: PubMed
    Score: 0.003
  155. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):433-441.
    View in: PubMed
    Score: 0.003
  156. Response to Comments by Drs Hamaoka and Beyea on "The Birth of the Illegitimate Linear No-Threshold Model: An Invalid Paradigm for Estimating Risk Following Low-dose Radiation Exposure". Am J Clin Oncol. 2017 02; 40(1):106-107.
    View in: PubMed
    Score: 0.003
  157. Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res. 2017 01 01; 23(1):321.
    View in: PubMed
    Score: 0.003
  158. Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 07 15; 98(4):900-907.
    View in: PubMed
    Score: 0.003
  159. Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):770-777.
    View in: PubMed
    Score: 0.003
  160. Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Non-small-cell Lung Cancer. Clin Lung Cancer. 2017 03; 18(2):141-148.
    View in: PubMed
    Score: 0.003
  161. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
    View in: PubMed
    Score: 0.003
  162. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203.
    View in: PubMed
    Score: 0.003
  163. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016 Jul-Aug; 22(4):257-66.
    View in: PubMed
    Score: 0.003
  164. Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. Pract Radiat Oncol. 2017 Jan - Feb; 7(1):63-71.
    View in: PubMed
    Score: 0.003
  165. Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control. Cancer J. 2016 Mar-Apr; 22(2):130-7.
    View in: PubMed
    Score: 0.003
  166. Single Nucleotide Polymorphisms in CBLB, a?Regulator of T-Cell Response, Predict Radiation Pneumonitis and Outcomes After Definitive Radiotherapy for Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2016 07; 17(4):253-262.e5.
    View in: PubMed
    Score: 0.003
  167. Cost-effectiveness of stereotactic radiation, sublobar resection, and lobectomy for early non-small cell lung cancers in older adults. J Geriatr Oncol. 2015 Jul; 6(4):324-31.
    View in: PubMed
    Score: 0.002
  168. Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2015 Jun 01; 92(2):317-24.
    View in: PubMed
    Score: 0.002
  169. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA Surg. 2014 Dec; 149(12):1244-53.
    View in: PubMed
    Score: 0.002
  170. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
    View in: PubMed
    Score: 0.002
  171. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
    View in: PubMed
    Score: 0.002
  172. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56.
    View in: PubMed
    Score: 0.002
  173. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.002
  174. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014 Oct; 9(10):1554-60.
    View in: PubMed
    Score: 0.002
  175. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014 Aug; 112(2):256-61.
    View in: PubMed
    Score: 0.002
  176. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role? J Thorac Oncol. 2014 Aug; 9(8):1202-6.
    View in: PubMed
    Score: 0.002
  177. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014 Mar 15; 120(6):790-8.
    View in: PubMed
    Score: 0.002
  178. What would be the most appropriate a/? ratio in the setting of stereotactic body radiation therapy for early stage non-small cell lung cancer. Biomed Res Int. 2013; 2013:391021.
    View in: PubMed
    Score: 0.002
  179. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.002
  180. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.002
  181. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.
    View in: PubMed
    Score: 0.002
  182. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer. Cancer. 2013 Sep 15; 119(18):3402-10.
    View in: PubMed
    Score: 0.002
  183. Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg. 2013 Aug; 17(8):1359-69.
    View in: PubMed
    Score: 0.002
  184. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy. PLoS One. 2013; 8(4):e59729.
    View in: PubMed
    Score: 0.002
  185. New era of radiotherapy: an update in radiation-induced lung disease. Clin Radiol. 2013 Jun; 68(6):e275-90.
    View in: PubMed
    Score: 0.002
  186. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
    View in: PubMed
    Score: 0.002
  187. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol. 2013 May; 24(5):1312-9.
    View in: PubMed
    Score: 0.002
  188. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012 Dec 01; 84(5):1060-70.
    View in: PubMed
    Score: 0.002
  189. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.002
  190. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811.
    View in: PubMed
    Score: 0.002
  191. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013 Jun; 52(5):1002-9.
    View in: PubMed
    Score: 0.002
  192. Outcome of trimodality-eligible esophagogastric cancer patients who declined surgery after preoperative chemoradiation. Oncology. 2012; 83(5):300-4.
    View in: PubMed
    Score: 0.002
  193. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer. Eur J Cancer. 2012 Dec; 48(18):3396-404.
    View in: PubMed
    Score: 0.002
  194. Dosimetric selection for helical tomotherapy based stereotactic ablative radiotherapy for early-stage non-small cell lung cancer or lung metastases. PLoS One. 2012; 7(4):e35809.
    View in: PubMed
    Score: 0.002
  195. Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. Cancer Sci. 2012 May; 103(5):945-50.
    View in: PubMed
    Score: 0.002
  196. Postmastectomy radiotherapy with integrated scar boost using helical tomotherapy. Med Dosim. 2012; 37(3):233-9.
    View in: PubMed
    Score: 0.002
  197. Nomograms for prognostication of outcome in patients with esophageal and gastroesophageal carcinoma undergoing definitive chemoradiotherapy. Oncology. 2012; 82(2):108-13.
    View in: PubMed
    Score: 0.002
  198. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012; 195:151-61.
    View in: PubMed
    Score: 0.002
  199. Neoadjuvant chemoradiotherapy followed by surgery for esophageal adenocarcinoma: significance of microscopically positive circumferential radial margins. J Thorac Cardiovasc Surg. 2012 Feb; 143(2):412-20.
    View in: PubMed
    Score: 0.002
  200. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg. 2012 Jan; 93(1):207-12; discussion 212-3.
    View in: PubMed
    Score: 0.002
  201. Stereotactic body radiation therapy in non-small-cell lung cancer: linking radiobiological modeling and clinical outcome. Am J Clin Oncol. 2011 Aug; 34(4):432-41.
    View in: PubMed
    Score: 0.002
  202. Celebrate or calibrate? We say calibrate. J Clin Oncol. 2011 Jul 01; 29(19):2732; author reply 2732-3.
    View in: PubMed
    Score: 0.002
  203. Prognostic significance of baseline positron emission tomography and importance of clinical complete response in patients with esophageal or gastroesophageal junction cancer treated with definitive chemoradiotherapy. Cancer. 2011 Nov 01; 117(21):4823-33.
    View in: PubMed
    Score: 0.002
  204. Feasibility of helical tomotherapy in stereotactic body radiation therapy for centrally located early stage non?small-cell lung cancer or lung metastases. Int J Radiat Oncol Biol Phys. 2011 Nov 01; 81(3):856-62.
    View in: PubMed
    Score: 0.002
  205. Helical tomotherapy versus single-arc intensity-modulated arc therapy: a collaborative dosimetric comparison between two institutions. Int J Radiat Oncol Biol Phys. 2011 Sep 01; 81(1):284-96.
    View in: PubMed
    Score: 0.002
  206. Exploring the feasibility of dose escalation positron emission tomography-positive disease with intensity-modulated radiation therapy and the effects on normal tissue structures for thoracic malignancies. Med Dosim. 2011; 36(4):383-8.
    View in: PubMed
    Score: 0.002
  207. Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 2011 Mar 01; 79(3):835-41.
    View in: PubMed
    Score: 0.002
  208. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. Anticancer Res. 2010 Mar; 30(3):953-61.
    View in: PubMed
    Score: 0.002
  209. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2010 Feb 01; 76(2):326-32.
    View in: PubMed
    Score: 0.002
  210. Safety and effectiveness of vascular endoprosthesis for malignant superior vena cava syndrome. Thorax. 2009 Feb; 64(2):174-8.
    View in: PubMed
    Score: 0.002
  211. Microscopic and macroscopic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1414-24.
    View in: PubMed
    Score: 0.002
  212. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer. Oncology. 2008; 75(3-4):186-91.
    View in: PubMed
    Score: 0.002
  213. Can stereotactic fractionated radiation therapy become the standard of care for early stage non-small cell lung carcinoma. Cancer Treat Rev. 2008 Dec; 34(8):719-27.
    View in: PubMed
    Score: 0.002
  214. Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region. Breast Cancer Res Treat. 2009 Mar; 114(2):307-13.
    View in: PubMed
    Score: 0.002
  215. Helical tomotherapy as a means of administering total or partial scalp irradiation: In regards to Bedford et al. (Int J Radiat Oncol Biol Phys 2005;62:1549-1558). Int J Radiat Oncol Biol Phys. 2006 Mar 15; 64(4):1288-9; author reply 1289-90.
    View in: PubMed
    Score: 0.001
  216. American Society for Therapeutic Radiology and Oncology and American College of Radiology practice guideline for the performance of stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2004 Nov 15; 60(4):1026-32.
    View in: PubMed
    Score: 0.001
  217. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2003 Sep 01; 57(1):166-71.
    View in: PubMed
    Score: 0.001
  218. Acute and late radiotherapy toxicity in patients with inflammatory bowel disease. Int J Radiat Oncol Biol Phys. 2001 Oct 01; 51(2):455-9.
    View in: PubMed
    Score: 0.001
  219. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14717-22.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.